Expanded Access to RXDX-105 for Cancers With RET Alterations
- Conditions
- Cancers With RET Alterations
- Registration Number
- NCT03052569
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Diagnosis of advanced cancer with RET alterations
- Unable to participate in an ongoing RXDX-105 clinical trial
- Willing and able to provide written, signed informed consent
- Medically suitable for treatment with RXDX-105
Read More
Exclusion Criteria
- Prior treatment with a TKI that has activity against RET alterations
- Currently enrolled in an ongoing clinical study with any other investigational agent
Read More
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Www.Ignyta.Com
🇺🇸San Diego, California, United States